Acumen Pharmaceuticals Reports Third-Quarter 2026 Net Loss of $25.4 Million
Acumen reported a diluted loss per share of $0.35, narrowed from $0.44 a year earlier. Its net loss was $25.4 million, compared with $26.5 million in the year-ago quarter.
Acumen Pharmaceuticals reported a net loss of $25.4 million for the third quarter of 2026, compared with a $26.5 million loss a year earlier, while diluted loss per share narrowed to $0.35 from $0.44. Research and development expenses declined year over year as manufacturing and CRO activity eased…